Tagged with MENA

UAE With a relatively high number of genetic disorders, the Arab population of the United Arab Emirates (UAE) is increasingly becoming the subject of new studies. The database from the Center for Arab Genomics Studies indicates the presence of 241 genetic disorders among that demographic, a number they call “extremely high…

Saudi Arabia Saudi Arabia is aiming to become a more attractive investment destination for multinational pharma companies through economic development projects that facilitate ease of doing business. Not stopping there, the Kingdom has a bold ambition to become a pharma hub for the entire Middle East region.    Saudi Arabia has the…

Pharma Faces Paolo Carli, head of Middle East, Africa, Turkey, Russia and CIS (MEAR) for Merck has continually taken on greater responsibilities in the Middle East, Africa, Turkey and Eastern Europe. In his most recent interview with PharmaBoardroom, Carli talks strategy, adaptability, and sales growth.    We look at structuring markets with…

UAE Khaled Elrefae, Middle East and Africa Specialty Care Operations Head (GM) for Ipsen, highlights Ipsen’s impressive internationalization strategy and the success factors as well as rationale behind the company entrance to the MEA market with the newly established affiliate in UAE. He then discusses his mandate to drive a transformation…

Merck Since we last met with Paolo Carli in 2013, he has been given greater responsibilities within Merck and is now Head of Middle East, Africa, Turkey, Russia, and CIS countries for the healthcare business. Paolo discusses the logic behind being assigned such a vast region to manage, Merck’s strategy for…

UAE The UAE ranks as a world leader in rapid drug approvals with its fast-track registration system that accelerates the process and eliminates long waiting times for innovative and orphan drugs.   If you bring innovation, the [UAE] government will support you on all levels Georg Schroeckenfuchs, Novartis In January 2018…

UAE PharmaBoardroom highlights three pharma executives whose experience in the Middle East has served to propel them into global leadership positions.   The Middle East and North Africa region is comprised of 22 countries and has a population of nearly 400 million. The region is home to a fast-growing pharma market…

UAE The top 10 pharma companies in the UAE ranked by 2018 sales according to IQVIA data. Swiss giant Novartis leads the way with USD 196 million in sales, followed by GSK on 129 million and AstraZeneca with 126 million.   Made with Visme Infographic Maker

Thailand As the general manager of Menarini Thailand, Thomas Scott Birsinger shares the importance of the Thai affiliate within the company’s operations in the region. He also describes its efforts to work closely with both the government and industry to help ensure access to the most crucial medicines across very diverse…

MENA The Middle East and North Africa (MENA) region’s pharmaceutical market is projected to reach a value of around USD 60 billion by 2025 according to reporting from TradeArabia. The most impressive growth is coming from the UAE, but North African giants Egypt and Algeria are also significant contributors.   Factors…

Turkey Uğur Bingöl, general manager of Ibrahim Etem Menarini, speaks of his company’s rapid growth and new product lines. He also describes his take on the Turkish pharmaceutical market and outlines his strategic priorities to continue growing Ibrahim Etem Menarini’s presence in Turkey.   We are committed to the localization movement…

Pharma The country manager of Berlin-Chemie / A. Menarini Hungary, Dr. Peter Olah, explains the impact of a more targeted sales force in driving the company in the last three years, while highlighting his ambitions to push the affiliate into more specialty care. He also describes the most salient challenges currently…